Biotechnology Value Fund

Biotechnology Value Fund

Pulse 2.0

Olema Pharmaceuticals (OLMA) Stock: Why The Price Increased 9.22% Today

Pulse 2.0

Blueprint Medicines (BPMC) Stock: Why The Price Fell Today

Pulse 2.0

Olema Pharmaceuticals (OLMA) Stock: Why The Price Jumped Today

MedCity News

Blueprint Medicines to buy cancer drug startup with potential edge over Takeda, J&J targeted therapies

$2,000,000,000
Reuters Top News

Bayer buys biopharma firm Vividion Therapeutics for up to $2 bln

neurons.AI

Relay Therapeutics Snaps up ZebiAI with $85 Million Upfront Payment

$85,000,000 Venture capital (Series C)
FinSMEs

Olema Oncology Raises $85M in Series C Financing

MedCity News

FDA green-lights second RET inhibitor, this time from Blueprint Medicines

Xconomy

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

$54,000,000 Venture capital (Series B)
Pulse 2.0 , FinSMEs

Olema Oncology Secures $54 Million To Advance Lead Program In Breast Cancer

MedCity News

Relay Therapeutics prices IPO at $400M

Bloomberg Technology

SoftBank-Backed Relay Therapeutics Seeks $265 Million in IPO

MedCity News

Protein motion-focused Relay Therapeutics files for $200M IPO

$76,000,000 Venture capital (Series B)
Pulse 2.0

Autobahn Therapeutics Raises $76 Million To Develop Therapies For CNS Disorders

FinSMEs

Autobahn Therapeutics Raises $76M in Series B Financing

the home of AI info

Evotec, Takeda Enter Long-Term Research Alliance

$102,000,000 Venture capital (Series C)
FinSMEs

Kymera Therapeutics Raises $102M in Series C Financing

Xconomy

Evotec CEO Discusses Ways to Make Drug R&D Faster and Better

$181,700,000 IPO
PE HUB

Phathom Pharmaceuticals goes public

$400,000,000 Venture capital (Series C)
FinSMEs , PE HUB , VentureBeat

Relay Therapeutics Secures $400M in Series C Financing